Literature DB >> 19244040

Tumor burden in patients with neurofibromatosis types 1 and 2 and schwannomatosis: determination on whole-body MR images.

Wenli Cai1, Ara Kassarjian, Miriam A Bredella, Gordon J Harris, Hiroyuki Yoshida, Victor F Mautner, Ralph Wenzel, Scott R Plotkin.   

Abstract

PURPOSE: To develop a three-dimensional (3D) segmentation and computerized volumetry technique for use in the assessment of neurofibromatosis and to assess the ability of this technique to aid in the calculation of tumor burden in patients with neurofibromatosis types 1 and 2 (NF1 and NF2, respectively) and schwannomatosis detected with whole-body magnetic resonance (MR) imaging.
MATERIALS AND METHODS: Institutional review board approval and written informed consent were obtained for this prospective HIPAA-compliant study. Fifty-two subjects (27 women, 25 men; mean age, 42 years +/- 15 [standard deviation]; age range, 24-86 years) underwent whole-body MR imaging performed with coronal short inversion time inversion-recovery (STIR) sequences. Whole-body tumor burden was estimated with a 3D segmentation method (the dynamic-threshold [DT] level set method) in 29 subjects (16 with NF1, six with NF2, and seven with schwannomatosis) in whom at least one nerve sheath tumor was reliably identified on MR images. Fifty tumors (25 plexiform and 25 discrete tumors) were randomly selected and subjected to manual and computerized volumetry to assess reliability. Ten plexiform tumors 5 cm or larger in diameter were retrospectively selected and segmented with three initialization methods for computerized volumetry and manually contoured by three radiologists to assess repeatability. Bland-Altman analysis was performed, and intraclass correlation coefficients (ICCs) were calculated.
RESULTS: A total of 398 nerve sheath tumors (185 plexiform and 213 discrete tumors) were identified in 29 subjects. Volumetric measurements obtained with the computerized method and manual contouring were highly correlated (r(ICC) = 0.99). Bland-Altman analysis showed that computerized volumetry had a mean difference of -2.6% compared with manual volumetry. The repeatability coefficient of the computerized scheme was +/-5% compared with +/-30% for manual contouring.
CONCLUSION: This 3D segmentation and computerized volumetry technique is reliable relative to manual segmentation and has the advantage of being less labor intensive and more repeatable. This technique can be paired with whole-body MR imaging to determine tumor burden in patients with neurofibromatosis. SUPPLEMENTAL MATERIAL: http://radiology.rsnajnls.org/cgi/content/full/250/3/665/DC1 RSNA, 2009

Entities:  

Mesh:

Year:  2009        PMID: 19244040     DOI: 10.1148/radiol.2503080700

Source DB:  PubMed          Journal:  Radiology        ISSN: 0033-8419            Impact factor:   11.105


  41 in total

1.  Whole-body MRI in neurofibromatosis: incidental findings and prevalence of scoliosis.

Authors:  Jacob L Jaremko; Peter J MacMahon; Martin Torriani; Vanessa L Merker; Victor F Mautner; Scott R Plotkin; Miriam A Bredella
Journal:  Skeletal Radiol       Date:  2011-12-07       Impact factor: 2.199

Review 2.  Whole-body MR imaging, bone diffusion imaging: how and why?

Authors:  Diego Jaramillo
Journal:  Pediatr Radiol       Date:  2010-04-30

Review 3.  [Cranial nerves - spectrum of inflammatory and tumorous changes].

Authors:  S F Nemec; G Kasprian; U Nemec; C Czerny
Journal:  Radiologe       Date:  2009-07       Impact factor: 0.635

Review 4.  Current status of sporadic and neurofibromatosis type 1-associated malignant peripheral nerve sheath tumors.

Authors:  Brigitte C Widemann
Journal:  Curr Oncol Rep       Date:  2009-07       Impact factor: 5.075

5.  Radiomic biomarkers informative of cancerous transformation in neurofibromatosis-1 plexiform tumors.

Authors:  J Uthoff; F A De Stefano; K Panzer; B W Darbro; T S Sato; R Khanna; D E Quelle; D K Meyerholz; J Weimer; J C Sieren
Journal:  J Neuroradiol       Date:  2018-06-27       Impact factor: 3.447

Review 6.  Current status of MEK inhibitors in the treatment of plexiform neurofibromas.

Authors:  Andrea M Gross; Eva Dombi; Brigitte C Widemann
Journal:  Childs Nerv Syst       Date:  2020-06-30       Impact factor: 1.475

7.  Whole-body imaging in schwannomatosis.

Authors:  Avneesh Chhabra; Jaishri Blakely
Journal:  Neurology       Date:  2011-06-07       Impact factor: 9.910

8.  Phase II trial of pirfenidone in children and young adults with neurofibromatosis type 1 and progressive plexiform neurofibromas.

Authors:  Brigitte C Widemann; Dusica Babovic-Vuksanovic; Eva Dombi; Pamela L Wolters; Stewart Goldman; Staci Martin; Anne Goodwin; Wendy Goodspeed; Mark W Kieran; Bruce Cohen; Susan M Blaney; Allison King; Jeffrey Solomon; Nicholas Patronas; Frank M Balis; Elizabeth Fox; Seth M Steinberg; Roger J Packer
Journal:  Pediatr Blood Cancer       Date:  2014-04-22       Impact factor: 3.167

Review 9.  Magnetic resonance neurography of median neuropathies proximal to the carpal tunnel.

Authors:  Gaurav K Thawait; Ty K Subhawong; Shrey K Thawait; Gustav Andreisek; Alan J Belzberg; John Eng; John A Carrino; Avneesh Chhabra
Journal:  Skeletal Radiol       Date:  2012-03-18       Impact factor: 2.199

Review 10.  High-resolution 3T MR neurography of the brachial plexus and its branches, with emphasis on 3D imaging.

Authors:  A Chhabra; G K Thawait; T Soldatos; R S Thakkar; F Del Grande; M Chalian; J A Carrino
Journal:  AJNR Am J Neuroradiol       Date:  2012-09-13       Impact factor: 3.825

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.